| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
|
Takasaki, Kazuki
|
|
2018
|
81 |
5 |
p. 809-814
|
artikel
|
| 2 |
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib
|
Deng, Mengyan
|
|
2018
|
81 |
5 |
p. 853-862
|
artikel
|
| 3 |
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
|
Kimura, Kosei
|
|
2018
|
81 |
5 |
p. 923-933
|
artikel
|
| 4 |
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial
|
Munemoto, Yoshinori
|
|
2018
|
81 |
5 |
p. 829-838
|
artikel
|
| 5 |
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma
|
El-Khoueiry, Anthony B.
|
|
2018
|
81 |
5 |
p. 957-963
|
artikel
|
| 6 |
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
|
Dean, Emma
|
|
2018
|
81 |
5 |
p. 873-883
|
artikel
|
| 7 |
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin
|
Kudlowitz, David
|
|
2018
|
81 |
5 |
p. 847-851
|
artikel
|
| 8 |
Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1
|
Yin, Peng
|
|
2018
|
81 |
5 |
p. 863-872
|
artikel
|
| 9 |
Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab
|
Nomura, Motoo
|
|
2018
|
81 |
5 |
p. 823-827
|
artikel
|
| 10 |
EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
|
Huang, Thomas
|
|
2018
|
81 |
5 |
p. 965-968
|
artikel
|
| 11 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
|
Sy, Sherwin K. B.
|
|
2018
|
81 |
5 |
p. 897-909
|
artikel
|
| 12 |
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B
|
Xiao, Fang
|
|
2018
|
81 |
5 |
p. 935-947
|
artikel
|
| 13 |
Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients
|
Kurata, Keiji
|
|
2018
|
81 |
5 |
p. 839-846
|
artikel
|
| 14 |
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
|
Yamada, Suguru
|
|
2018
|
81 |
5 |
p. 815-821
|
artikel
|
| 15 |
Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
|
Velden, Daphne L. van der
|
|
2018
|
81 |
5 |
p. 911-921
|
artikel
|
| 16 |
Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study
|
Matsuyama, Ryusei
|
|
2018
|
81 |
5 |
p. 949-955
|
artikel
|
| 17 |
Sodium selenite attenuates lung adenocarcinoma progression by repressing SOX2-mediated stemness
|
Chen, Weiwei
|
|
2018
|
81 |
5 |
p. 885-895
|
artikel
|
| 18 |
Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases
|
Ying, Jie
|
|
2018
|
81 |
5 |
p. 797-808
|
artikel
|
Tijdschrift beschrijving